

## **Bilcare announces its Q3 FY10 results**

**Pune, February 01, 2010:** Consolidated Sales for the quarter ended December 31, 2009 stood at Rs.276.49 crores, showing a growth of 31.24% over the corresponding quarter of the previous year; with the Consolidated EBITDA growing to Rs.69.35 crores from Rs.45.99 crores, a growth of 50.79%.

The Consolidated Sales for a nine month period ended December 31, 2009 stood at Rs.778.25 crores as against Rs.609.21 crores in the corresponding period of previous year, resulting in EBIDTA of Rs.187.53 Cr and Net Profit of Rs.82.09Cr , a growth of 27.74 % in Consolidated Sales and 51.62% in Net Profit.

The India Standalone Sales for the third quarter ended December 31, 2009 stood at Rs.140.11 crores as against Rs.117.10 crores in the same quarter of the previous year, showing a growth of 19.65%. This resulted in the EBITDA for India Standalone growing to Rs.42.45 crores from Rs.34.36 crores in the corresponding quarter of the previous year, showing a growth of 23.54%.

The Overseas business of the Company continued to show robust growth achieving Rs.136.38 crores in the third quarter of the current year from Rs.93.57 crores in corresponding quarter of the previous year, showing a growth of 45.75%. The EBITDA from Overseas business in the third quarter grew to Rs.26.90 crores from Rs.11.63 crores in the corresponding quarter of the previous year, resulting in a growth of 131.30%.

### **About Bilcare Research:**

Headquartered in India, Bilcare is an integrated service provider to the global pharmaceutical sector across their value chain through its key business activities namely: Pharma Packaging Innovation, Global Clinical Services and nonClonable Technologies. These business activities encompass research, development, manufacturing and supply of products, processes, and services to the Pharma and Healthcare domain. Technologies business focuses on unique range of applications viz. security & product authentication, Track & Trace e-pedigree, medication compliance & Personalized Healthcare Management System. Bilcare operates state-of-the-art Manufacturing and Research facilities in India, Singapore, USA & UK and has regional offices in Brazil, Germany, while partnering with the global pharmaceutical sector by providing value solutions to address their key concerns i.e. counterfeit, compliance, cost communication and convenience.

(Visit us at [www.bilcare.com](http://www.bilcare.com)) and

Bilcare Technologies website [www.bilcaretech.com](http://www.bilcaretech.com)

**Press Contact:**

Bilcare Research

Tel: +91 20 30257700

Email: [corpcomm@bilcare.com](mailto:corpcomm@bilcare.com)